1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 1999 GENELABS TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in Charter) California 0-19222 94-3010150 (State or Other Jurisdiction (Commission File No.) (IRS Employer of Incorporation) Identification No.) 505 Penobscot Drive Redwood City, CA 94063 (Address of Principal Executive Offices) Registrant's telephone number, including area code: (650) 369-9500 2 Item 5. Other Events On March 15, 1999, Genelabs Technologies, Inc. ("Genelabs" or the "Company"), a California corporation, announced that Dr. Irene A. Chow will be appointed Chairman of the Board of Directors effective April 1, 1999. Dr. Chow will be succeeded as President by James A.D. Smith, who was promoted from Chief Operating Officer. As part of her planned transition to retirement, Dr. Chow will resign as President and Chief Executive Officer but will remain actively involved as Chairman of the Board and will maintain an office at Genelabs. Item 7. Financial Statements and Exhibits (c) Exhibits 99.1 Text of press release dated March 15, 1999. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Genelabs Technologies, Inc. Dated: March 15, 1999 By: /s/ MATTHEW M. LOAR --------------------------------- Matthew M. Loar Vice President, Finance 3 INDEX TO EXHIBITS Exhibit Number Description - ------ ----------- 99.1 Text of press release dated March 15, 1999.